Skip to main content

Market Overview

Tonix Pharma Shares Rally After In-Licensing Of Technology For A Rare Genetic Eating Disorder

  • Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has licensed technology using oxytocin-based therapeutics from the French National Institute of Health and Medical Research (Inserm) for the treatment of Prader-Willi syndrome, characterized by a constant sense of hunger (hyperphagia), which leads to severe obesity resulting in physical, mental and behavioral problems.
  • The co-exclusive license allows Tonix to expand its intranasal potentiated oxytocin development program to a new indication, designated as TNX-2900 (intranasal potentiated oxytocin) to treat Prader-Willi syndrome.
  • The patents covering the technology are expected to provide market exclusivity for the U.S. and Europe's co-licensees through 2031.
  • The company plans to submit an application to the FDA for Orphan Drug and Fast Track designations for TNX-2900.
  • Price Action: TNXP gains 11.7% at $1.82 during premarket trading on the last check Thursday.

Related Articles (TNXP)

View Comments and Join the Discussion!

Posted-In: hyperphagia INSERMBiotech News Penny Stocks Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at